Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses the significance of the findings of her research on Ceftazidime-Avibactam.
Interview Transcript (slightly modified for readability)
“The findings of this research are significant because there’s not really a lot of data on this antibiotic [Ceftazidime-Avibactam] yet. It’s only been out a year and a half at this point,* and it’s only been approved for two indications: intra-abdominal infections and urinary tract infections. There hasn’t been anything reported, as of yet, on [the approval of the antibiotic to treat] other types of infections. I did recently see a case series of three patients that was reported, that was in other infections, but that’s all that’s been published so far in the US.
We really need data to show whether or not it’s good [to treat other infection]. We can’t say that for sure yet, but we need something to go off of to know if we should be using this.”
This interview was conducted at ID Week 2016.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Big advances in treatment can't make up for an inability to stop new infections, which number 5,000 per day worldwide.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512